This is not the most recent version of the article. View current version (12 SEP 2012)

Intervention Protocol

Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell/bone marrow transplantation

  1. Sebastian Theurich1,*,
  2. Hans Fischmann1,
  3. Alexander Shimabukuro-Vornhagen1,
  4. Nicole Skoetz2,
  5. Jens M Chemnitz1,
  6. Udo Holtick1,
  7. Christof Scheid1,
  8. Jan Beyersmann3,
  9. Michael von Bergwelt-Baildon1

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 15 JUN 2011

Assessed as up-to-date: 4 MAR 2011

DOI: 10.1002/14651858.CD009159


How to Cite

Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Skoetz N, Chemnitz JM, Holtick U, Scheid C, Beyersmann J, von Bergwelt-Baildon M. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell/bone marrow transplantation (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 6. Art. No.: CD009159. DOI: 10.1002/14651858.CD009159.

Author Information

  1. 1

    University Hospital of Cologne, Department I of Internal Medicine, Stem Cell Transplantation Program, Cologne, Germany

  2. 2

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

  3. 3

    University of Freiburg, Freiburg Center for Data Analysis and Modeling (FDM), Freiburg, Germany

*Sebastian Theurich, Department I of Internal Medicine, Stem Cell Transplantation Program, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. sebastian.theurich@uk-koeln.de.

Publication History

  1. Publication Status: New
  2. Published Online: 15 JUN 2011

SEARCH

This is not the most recent version of the article. View current version (12 SEP 2012)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the effectiveness of ATGs used for the prevention of GvHD after allogeneic HSCT with regard to overall survival, disease-free survival, relapse incidence, non-relapse mortality, acute GvHD grades I to IV, II to IV and III to IV, chronic GvHD (limited or extensive), incidence of infectious complications, other adverse effects and cause of deaths.